Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neflamapimod - EIP Pharma

Drug Profile

Neflamapimod - EIP Pharma

Alternative Names: VX-745

Latest Information Update: 17 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EIP Pharma; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antidementias; Nootropics; Pyridazines; Small molecules; Sulfides
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis; Stroke

Most Recent Events

  • 13 Dec 2018 EIP Pharma completes enrolment in the REVERSE-SD trial for Alzheimer Disease in USA, UK, Netherlands, Denmark and Czech Republic (NCT03402659)
  • 24 Jun 2018 Biomarkers information updated
  • 07 Mar 2018 Efficacy and pharmacokinetics data from a phase II trial in Alzheimer's disease released by EIP Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top